IGBA Launches Global Biosimilars Week

November 16, 2020
Tony Hagen

Tony Hagen is senior managing editor for The Center for Biosimilars®.

The International Generic and Biosimilar Medicines Association (IGBA) hopes to build momentum for the use of biosimilars.

The International Generic and Biosimilar Medicines Association (IGBA) has launched the first Global Biosimilars Week, an attempt to raise awareness of the value of biosimilars and provide resources for interested persons to find out more about these lower-cost agents

The website for Global Biosimilars Week contains patient testimonials, an introductory overview of biosimilars, and various other resources designed to explain the global reach biosimilars have achieved and their importance for extending treatment options.

“Enhanced knowledge of biosimilar medicines will support improved access to life-saving biological treatments and support healthcare systems, which are under increasing pressure due to the rising costs of innovative treatments and the new fiscal demands created by the Covid-19 global public health crisis,” said Hanan Sboul, chair of the IGBA.

IGBA is based in Geneva and is a trade association of companies that develop and market biosimilar medicines, which are often sold at significant discounts to innovator biologics and help to increase access to treatment for patients.

Global Biosimilars Week will continue through Friday, November 20. “Enhanced knowledge of biosimilar medicines will support improved access to life-saving biological treatments and support health care systems, which are under increasing pressure due to the rising costs of innovative treatments and the new fiscal demands created by the Covid-19 global public health crisis,” said Erika Satterwhite, chair of the IGBA biosimilars Committee.

The group is inviting interested members of the public to join an online discussion about biosimilars on social media this week using the hashtag #GlobalBiosimilarsWeek.


x